[1]    Wu YR, Hsing CH, Chiu CJ, Huang HY, Hsu YH. Roles of IL‐1 and IL‐10 family cytokines in the progression of systemic lupus erythematosus: Friends or foes?. IUBMB life. 2022 Feb; 74(2): 143-56. 
Google Scholar

[2]    Desai MK, Brinton RD. Autoimmune disease in women: endocrine transition and risk across the lifespan. Frontiers in endocrinology. 2019 Apr 29; 10: 265. 
Google Scholar

[3]    Fava A, Petri M. Systemic lupus erythematosus: diagnosis and clinical management. Journal of autoimmunity. 2019 Jan 1; 96: 1-3. 
Google Scholar

[4]    Pan L, Lu MP, Wang JH, Xu M, Yang SR. Immunological pathogenesis and treatment of systemic lupus erythematosus. World Journal of Pediatrics. 2020 Feb; 16: 19-30. 
Google Scholar

[5]    Altintas A, Dargvainiene J, Schneider-Gold C, Asgari N, Ayzenberg I, Ciplea AI, Junker R, Leypoldt F, Wandinger KP, Hellwig K. Gender issues of antibody-mediated diseases in neurology:(NMOSD/autoimmune encephalitis/MG). Therapeutic advances in neurological disorders. 2020 Aug; 13: 1756286420949808. 
Google Scholar

[6]    Sobhy N, Niazy MH, Kamal A. Lymphopenia in systemic lupus erythematosus patients: is it more than a laboratory finding?. The Egyptian Rheumatologist. 2020 Jan 1; 42(1): 23-6.
Google Scholar

[7]    Lee DS, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nature reviews Drug discovery. 2021 Mar; 20(3): 179-99. 
Google Scholar

[8]    Faustini F, Sippl N, Stålesen R, Chemin K, Dunn N, Fogdell-Hahn A, Gunnarsson I, Malmström V. Rituximab in systemic lupus erythematosus: transient effects on autoimmunity associated lymphocyte phenotypes and implications for immunogenicity. Frontiers in immunology. 2022; 13.
Google Scholar

[9]    de Candia P, Prattichizzo F, Garavelli S, Matarese G. T cells: warriors of SARS-CoV-2 infection. Trends in Immunology. 2021 Jan 1; 42(1): 18-30.
Google Scholar

[10]    Tavakolpour S, Rakhshandehroo T, Wei EX, Rashidian M. Lymphopenia during the COVID-19 infection: What it shows and what can be learned. Immunology letters. 2020 Sep; 225: 31.
Google Scholar

[11]    Soliman WM, Sherif NM, Ghanima IM, El-Badawy MA. Neutrophil to lymphocyte and platelet to lymphocyte ratios in systemic lupus erythematosus: relation with disease activity and lupus nephritis. Reumatología Clínica. 2020 Jul 1; 16(4): 255-61.
Google Scholar

[12]    Spihlman AP, Gadi N, Wu SC, Moulton VR. COVID-19 and systemic lupus erythematosus: focus on immune response and therapeutics. Frontiers in Immunology. 2020 Oct 30; 11: 589474.
Google Scholar

[13]    ElTanbouly MA, Noelle RJ. Rethinking peripheral T cell tolerance: checkpoints across a T cell’s journey. Nature Reviews Immunology. 2021 Apr; 21(4): 257-67.
Google Scholar

[14]    Oku K, Hamijoyo L, Kasitanon N, Li MT, Navarra S, Morand E, Tanaka Y, Mok CC. Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements. International Journal of Rheumatic Diseases. 2021 Jul; 24(7): 880-95.
Google Scholar

[15]    Fernandez-Ruiz R, Paredes JL, Niewold TB. COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. Translational Research. 2021 Jun 1; 232: 13-36.
Google Scholar

[16]    Elsayed SA, Mohafez OM. Autoantibodies spectrum in lupus nephritis in a cohort of Egyptian patients: relation to disease activity and prognostic value. Egyptian Rheumatology and Rehabilitation. 2020 Dec; 47: 1-0.
Google Scholar

[17]    Wu Y, Chen Y, Yang X, Chen L, Yang Y. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were associated with disease activity in patients with systemic lupus erythematosus. International Immunopharmacology. 2016 Jul; 36: 94–9.

[18]    Liu J, You M, Yao Y, Ji C, Wang Z, Wang F, Wang D, Qi Z, Yu G, Sun Z, Guo W. SRSF1 plays a critical role in invariant natural killer T cell development and function. Cellular & Molecular Immunology. 2021 Nov; 18(11): 2502-15.
Google Scholar

[19]    Katsuyama T, Martin-Delgado IJ, Krishfield SM, Kyttaris VC, Moulton VR. Splicing factor SRSF1 controls T cell homeostasis and its decreased levels are linked to lymphopenia in systemic lupus erythematosus. Rheumatology. 2020 Aug; 59(8): 2146-55.
Google Scholar

[20]    Farina AR, Cappabianca L, Sebastiano M, Zelli V, Guadagni S, Mackay AR. Hypoxia-induced alternative splicing: the 11th Hallmark of Cancer. Journal of Experimental & Clinical Cancer Research. 2020 Dec; 39: 1-30.
Google Scholar

[21]    Kandane-Rathnayake R, Louthrenoo W, Golder V, Luo SF, Wu YJJ, Lateef A, et al. Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational study. Rheumatology (Oxford, England). 2021 Nov 3; 60(11): 5185–93. 
Google Scholar

[22]    Gerosa M, Beretta L, Ramirez GA, Bozzolo E, Cornalba M, Bellocchi C, Argolini LM, Moroni L, Farina N, Segatto G, Dagna L. Long-Term clinical outcome in systemic lupus erythematosus patients followed for more than 20 years: the Milan systemic lupus erythematosus consortium (SMiLE) cohort. Journal of Clinical Medicine. 2022 Jun 22; 11(13): 3587.
Google Scholar

[23]    Kandane-Rathnayake R, Louthrenoo W, Golder V, Luo SF, Wu YJ, Lateef A, Cho J, Li Z, An Y, Hamijoyo L, Navarra S. Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational study. Rheumatology. 2021 Nov; 60(11): 5185-93.
Google Scholar

[24]    Tan MK, Heng TY, Mak A. The potential use of metformin, dipyridamole, N-acetylcysteine and statins as adjunctive therapy for systemic lupus erythematosus. Cells. 2019 Apr 6; 8(4): 323.
Google Scholar

[25]    Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, Wang J, Qin Y, Zhang X, Yan X, Zeng X. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clinical immunology. 2020 May 1; 214: 108393.
Google Scholar

[26]    Raja TW, Veeramuthu D, Savarimuthu I, Al-Dhabi NA. Current trends in the treatment of systemic lupus erythematosus. Current Pharmaceutical Design. 2020 Jun 1; 26(22): 2602-9.
Google Scholar

[27]    Téllez Arévalo AM, Quaye A, Rojas-Rodríguez LC, Poole BD, Baracaldo-Santamaría D, Tellez Freitas CM. Synthetic Pharmacotherapy for Systemic Lupus Erythematosus: Potential Mechanisms of Action, Efficacy, and Safety. Medicina. 2023 Jan; 59(1): 56.
Google Scholar

[28]    Tamirou F, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Fiehn C, Guttierez MD, Gilboe IM, Tektonidou M, Blockmans D, Ravelingien I. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Annals of the rheumatic diseases. 2016 Mar 1; 75(3): 526-31.
Google Scholar

[29]    Mejía-Vilet JM, Ayoub I. The use of glucocorticoids in lupus nephritis: new pathways for an old drug. Frontiers in medicine. 2021 Feb 16; 8: 622225.
Google Scholar

[30]    Durcan L, O'Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. The Lancet. 2019 Jun 8; 393(10188): 2332-43.
Google Scholar

[31]    Mackworth-Young CG, Fakhouri W, Feldman CH, et al. Incidence and severity of lymphopenia in patients with systemic lupus erythematosus treated with mycophenolate mofetil. Arthritis Res Ther. 2019; 21(1): 14. https://doi.org/10.1186/s13075-018-1802-2

[32]    Sánchez-Guerrero J, Pons-Estel GJ, Wallace DJ. Novel therapies for systemic lupus erythematosus. Lancet. 2018 Jan 27; 391(10126): 2172-83. https://doi.org/10.1016/S0140-6736(18)30403-5

[33]    Demirkaya E, Sahin S, Romano M, Zhou Q, Aksentijevich I. New horizons in the genetic etiology of systemic lupus erythematosus and lupus-like disease: monogenic lupus and beyond. Journal of clinical medicine. 2020 Mar 5; 9(3): 712.
Google Scholar

[34]    Musette P, Bouaziz JD. B cell modulation strategies in autoimmune diseases: new concepts. Frontiers in immunology. 2018 Apr 13; 9: 622.
Google Scholar

[35]    Wenzel J. Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. Nature Reviews Rheumatology. 2019 Sep; 15(9): 519-32.
Google Scholar

[36]    Zhang J, Roschke V, Baker KP, Wang Z, Alarcón GS, Fessler BJ, Bastian H, Kimberly RP, Zhou T. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol. 2001 Oct 15; 167(8): 3659-63. https://doi.org/10.4049/jimmunol.167.8.3659. PMID: 11591772
Google Scholar

[37]    Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF; BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 Dec; 63(12): https://doi.org/3918-30. 10.1002/art.30613
Google Scholar

[38]    Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford). 2005 Oct; 44(10). https://doi.org/1265-72. 10.1093/rheumatology/kei025
Google Scholar

[39]    Chan VS, Tsang HH, Tam RC, Lu L, Lau CS. B-cell-targeted therapies in systemic lupus erythematosus. Cellular & molecular immunology. 2013 Mar; 10(2): 133-42. https://doi.org/10.1038/cmi.2012.64
Google Scholar

[40]    Al-Rawi SS, Ibrahim AH, Ab Rahman NN, Nama MM, Majid AM, Ab Kadir MO. The effect of supercritical fluid extraction parameters on the nutmeg oil extraction and its cytotoxic and antiangiogenic properties. Procedia Food Science. 2011 Jan 1; 1: 1946-52.
Google Scholar

[41]    Ibrahim AH, Li H, Al-Rawi SS, Majid AS, Al-Habib OA, Xia X, Majid AM, Ji D. Angiogenic and wound healing potency of fermented virgin coconut oil: in vitro and in vivo studies. American journal of translational research. 2017; 9(11): 4936.
Google Scholar

[42]    Ibrahim AH, Al-Rawi SS, Majid AA, Rahman NA, Abo-Salah KM, Ab Kadir MO. Separation and fractionation of Aquilaria malaccensis oil using supercritical fluid extraction and tthe cytotoxic properties of the extracted oil. Procedia Food Science. 2011 Jan 1; 1: 1953-9.
Google Scholar

[43]    Dahham SS, Al-Rawi SS, Ibrahim AH, Majid AS, Majid AM. Antioxidant, anticancer, apoptosis properties and chemical composition of black truffle Terfezia claveryi. Saudi journal of biological sciences. 2018 Dec 1; 25(8): 1524-34.
Google Scholar

[44]    Le TH, Kwon SM. Vascular endothelial growth factor biology and its potential as a therapeutic target in rheumatic diseases. International Journal of Molecular Sciences. 2021 May 20; 22(10): 5387.
Google Scholar

[45]    Moschetti L, Piantoni S, Vizzardi E, Sciatti E, Riccardi M, Franceschini F, Cavazzana I. Endothelial dysfunction in systemic lupus erythematosus and systemic sclerosis: A common trigger for different microvascular diseases. Frontiers in Medicine. 2022; 9.
Google Scholar

[46]    Atehortúa L, Rojas M, Vásquez GM, Castaño D. Endothelial alterations in systemic lupus erythematosus and rheumatoid arthritis: potential effect of monocyte interaction. Mediators of inflammation. 2017 Oct; 2017.

[47]    El-Gazzar II, Ibrahim SE, El-Sawy WS, Fathi HM, Eissa AH. Assessment of vascular endothelial growth factor in systemic lupus erythematosus patients with anti-phospholipid syndrome. The Egyptian Rheumatologist. 2019: 41(1): 41-45.
Google Scholar

[48]    Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S, Ciołkiewicz M. Vascular endothelial growth factor in systemic lupus erythematosus: relationship to disease activity, systemic organ manifestation, and nailfold capillaroscopic abnormalities. Archivum immunologiae et therapiae experimentalis. 2007 Jun; 55: 179-85.
Google Scholar

[49]    Davidson A. What is damaging the kidney in lupus nephritis?. Nature Reviews Rheumatology. 2016 Mar; 12(3): 143-53.
Google Scholar

[50]    Carvalho JF, Blank M, Shoenfeld Y. Vascular endothelial growth factor (VEGF) in autoimmune diseases. Journal of clinical immunology. 2007 May; 27(3): 246-56.
Google Scholar

[51]    Fava A, Petri M. Systemic lupus erythematosus: diagnosis and clinical management. Journal of autoimmunity. 2019 Jan 1; 96: 1-3. https://doi.org/10.1016/j.jaut.2018.11.002
Google Scholar

[52]    Shimizu M, Iwamoto N, Yoshida T, et al. Glucocorticoids and cyclophosphamide inhibit endothelial expression of VEGF receptors. Laboratory Investigation. 2010; 90(1): 52-60. https://doi.org/10.1038/labinvest.2009.117

[53]    Bracchitta G, Catalfo A, Martineau S, Sage E, De Guidi G, Girard PM. Investigation of the phototoxicity and cytotoxicity of naproxen, a non-steroidal anti-inflammatory drug, in human fibroblasts. Photochemical & Photobiological Sciences. 2013 May; 12(5): 911-22.
Google Scholar

[54]    National Institute of Arthritis and Musculoskeletal and Skin Diseases. Systemic Lupus Erythematosus (Lupus). Bethesda, MD: National Institutes of Health; 2019. Available from: https://www.niams.nih.gov/health-topics/lupus

[55]    Furie R. Combination therapy in lupus nephritis. Journal of Rheumatology. 2019: 46(suppl 91): 26-28. https://doi.org/10.3899/jrheum.190299

[56]    Zhang L, Li L, Liu Y. Immunosuppressive therapy for lupus nephritis. Mediators Inflamm. 2014; 2014: 830472.

[57]    Teng YO, Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, Gordon D, Groark J, Henderson RB, Oldham M, Tak PP. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. BMJ open. 2019 Mar 1; 9(3): e025687.
Google Scholar

[58]    Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, Cervera R, Doria A, Gordon C, Govoni M, Houssiau F. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the rheumatic diseases. 2019 Jun 1; 78(6): 736-45. https://doi.org/10.1136/annrheumdis-2019-215089
Google Scholar

[59]    Dhir V, Aggarwal A, Lawrence A. Combination therapy for lupus nephritis: a review. ISRN Rheumatology. 2017: 3987405. https://doi.org/10.1155/2017/3987405

[60]    Jiang Y, Tian X, Gu Y, Li F, Wang X. Application of plasma exchange in steroid-responsive encephalopathy. Frontiers in Immunology. 2019: 324.
Google Scholar

[61]    Cervera R, Khamashta MA, Hughes GR. The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe. Lupus. 2009 Sep; 18(10): 869-74. https://doi.org/10.1177/096120339700600204
Google Scholar

[62]    Soyuöz A, Karadağ Ö, Karaağaç T, Kılıç L, Bilgen ŞA, Özcebe Oİ. Therapeutic plasma exchange for refractory SLE: a comparison of outcomes between different sub-phenotypes. European journal of rheumatology. 2018 Mar; 5(1): 32. 
Google Scholar

@article{al-rawi,sawsansandibrahim,ahmadhandahmedgasheenb2023,
 author = {Al- Rawi, Sawsan S and Ibrahim, Ahmad H and Ahmed Gasheen B},
 title = {Unraveling The Link Between Lymphopenia And Systemic Lupus Erythematosus: Implications For Disease Severity And Potential Treatment Strategies},
 journal = {Eurasian J. Sci. Eng},
 volume = {9},
 number = {2},
 pages = {231-240},
 year = {2023}
}